Sold as Fiorinal W/Codeine. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 16, 2026, FDA lists 6 applications for Aspirin; Butalbital; Caffeine; Codeine Phosphate (sold as Fiorinal W/Codeine), first approved Oct 26, 1990, with 0 new uses approved and 0 published complete response letters.
| Oct 26, 1990 | Fiorinal W/CodeineNDA 19429 ยท New combination | Allergan | 28 | Discontinued |
| Aug 31, 1995 | Butalbital, Aspirin, Caffeine, And Codeine PhosphateANDA 74359 | Watson Labs | 6 | Discontinued |
| Aug 31, 1998 | Butalbital, Aspirin, Caffeine, And Codeine PhosphateANDA 74951 | Stevens J | 9 | Marketed |
| Mar 5, 1999 | Butalbital, Aspirin, Caffeine, And Codeine PhosphateANDA 75351 | Novitium Pharma | 11 | Discontinued |
| Nov 30, 2001 | Butalbital, Aspirin, Caffeine, And Codeine PhosphateANDA 75231 | Lgm Pharma | 13 | Marketed |
| Oct 30, 2015 | Butalbital, Aspirin, Caffeine, And Codeine PhosphateANDA 203335 | Dr Reddys Labs SA | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA